WO2000063241A3 - Methods and compositions for modulating an immune response - Google Patents

Methods and compositions for modulating an immune response Download PDF

Info

Publication number
WO2000063241A3
WO2000063241A3 PCT/US2000/010340 US0010340W WO0063241A3 WO 2000063241 A3 WO2000063241 A3 WO 2000063241A3 US 0010340 W US0010340 W US 0010340W WO 0063241 A3 WO0063241 A3 WO 0063241A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteopontin
eta
methods
modulating
immunomodulatory molecules
Prior art date
Application number
PCT/US2000/010340
Other languages
French (fr)
Other versions
WO2000063241A2 (en
WO2000063241A9 (en
Inventor
Samy Ashkar
Georg Weber
Melvyn Glimcher
Harvey Cantor
Original Assignee
Childrens Medical Center
Dana Farber Cancer Inst Inc
Samy Ashkar
Georg Weber
Melvyn Glimcher
Harvey Cantor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Dana Farber Cancer Inst Inc, Samy Ashkar, Georg Weber, Melvyn Glimcher, Harvey Cantor filed Critical Childrens Medical Center
Priority to MXPA01010332A priority Critical patent/MXPA01010332A/en
Priority to CA002370129A priority patent/CA2370129A1/en
Priority to IL14589100A priority patent/IL145891A0/en
Priority to EP00923454A priority patent/EP1175223A2/en
Priority to BR0009791-8A priority patent/BR0009791A/en
Priority to AU43575/00A priority patent/AU773350B2/en
Priority to JP2000612329A priority patent/JP2003517284A/en
Publication of WO2000063241A2 publication Critical patent/WO2000063241A2/en
Publication of WO2000063241A3 publication Critical patent/WO2000063241A3/en
Publication of WO2000063241A9 publication Critical patent/WO2000063241A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)

Abstract

The present invention features new approaches for modulating immune responses. In particular, the invention features methods for modulating type 1 immune responses in a subject using modulators of Eta-1(early T lymphocyte activation-1)/osteopontin. Examplary methods feature methods of treating infections, immune disorders and diseases, autoimmune disorders and diseases, various immunodeficiencies and cancer. Also provided are biosynthetic immunomodulatory molecules that include functional domains derived from Eta-1/osteopontin. Preferred biosynthetic immunomodulatory molecules include an IL-12 stimulatory domain derived from Eta-1/osteopontin or an IL-10 inhibitory domain derived from Eta-1/osteopontin. The immunomodulatory molecules of the present invention are capable of biasing an immune response in a subject towards a type 1 immune response. Accordingly, therapeutic uses are disclosed which are based on the biosynthetic immunomodulatory molecules of the present invention.
PCT/US2000/010340 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response WO2000063241A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA01010332A MXPA01010332A (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response.
CA002370129A CA2370129A1 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response
IL14589100A IL145891A0 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response
EP00923454A EP1175223A2 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response
BR0009791-8A BR0009791A (en) 1999-04-15 2000-04-17 Methods to modulate, to potentiate and to down-regulate a type 1 immune response in a patient, to enhance the production of a cytokine associated with a type 1 immune response, to down-regulate the production of a cytokine associated with an immune response of type 2, to stimulate production of interleukin-12 (il-12) by a macrophage, to inhibit the production of interleukin-10 (il-10) by a macrophage, to produce an immunomodulatory molecule, and to modulate a response immune in a cell, modified tumor cells, and host, biosynthetic immunomodulatory molecules, and isolated nucleic acid, expression vector, and pharmaceutical composition
AU43575/00A AU773350B2 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response
JP2000612329A JP2003517284A (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12977299P 1999-04-15 1999-04-15
US60/129,772 1999-04-15

Publications (3)

Publication Number Publication Date
WO2000063241A2 WO2000063241A2 (en) 2000-10-26
WO2000063241A3 true WO2000063241A3 (en) 2001-05-10
WO2000063241A9 WO2000063241A9 (en) 2002-03-28

Family

ID=22441531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010340 WO2000063241A2 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response

Country Status (8)

Country Link
EP (1) EP1175223A2 (en)
JP (1) JP2003517284A (en)
AU (1) AU773350B2 (en)
BR (1) BR0009791A (en)
CA (1) CA2370129A1 (en)
IL (1) IL145891A0 (en)
MX (1) MXPA01010332A (en)
WO (1) WO2000063241A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101973D0 (en) * 2001-01-25 2001-03-14 Statens Seruminstitut Improved in vitro diagnostic method of detecting a cell-mediated immune response
JP2002221520A (en) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd Prediction method for immunology type
CA2446666A1 (en) * 2001-05-09 2002-11-14 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
YU89503A (en) 2001-05-17 2006-05-25 Applied Research System Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases
GB0116185D0 (en) * 2001-07-02 2001-08-22 Imp College Innovations Ltd Substances
HUP0402049A3 (en) 2001-09-25 2009-04-28 Astellas Pharma Inc Recombinant anti-osteopontin antibody and use thereof
BR0312042A (en) * 2002-06-25 2005-05-24 Aventis Pharma Inc Osteopontin, oligodendrocytes and myelination
WO2004013311A2 (en) 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
JPWO2004103403A1 (en) * 2003-05-23 2006-07-20 株式会社 免疫生物研究所 Immunocompetent cell activation inhibitors and uses thereof
WO2005100562A1 (en) * 2004-04-12 2005-10-27 Gene Techno Science Co., Ltd. OSTEOPONTIN siRNA
CA2667263C (en) * 2006-10-26 2016-11-08 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
CN101293916A (en) * 2007-04-24 2008-10-29 上海国健生物技术研究院 Monoclone antibody with combined function epiposition, specificity of osteopontin and uses thereof
CN102027013B (en) 2008-04-24 2015-01-14 株式会社遗传科技 Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
CA2726885A1 (en) * 2008-06-06 2009-12-10 Gene Techno Science Co., Ltd. Sirna of human osteopontin
AU2010299017B2 (en) 2009-09-24 2014-02-06 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
CA2858379A1 (en) * 2011-12-07 2013-06-13 Arla Foods Amba Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants
NZ715430A (en) 2013-07-05 2022-01-28 Arla Foods Amba Mammalian milk osteopontin for enhancing immune responsiveness
US10512673B2 (en) 2015-01-07 2019-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease
CN112040973B (en) 2018-04-25 2022-03-29 合生元（广州）健康产品有限公司 Combination of osteopontin and 2' -fucosyllactose for use as a medicament
WO2022226049A1 (en) * 2021-04-20 2022-10-27 University Of Cincinnati A vaccine adjuvant for infectious diseases
CN115707772A (en) * 2021-08-18 2023-02-21 澳门大学 Inducer, macrophage and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASHKAR SAMY ET AL: "Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity.", SCIENCE (WASHINGTON D C)., vol. 287, no. 5454, 4 February 2000 (2000-02-04), pages 860 - 864, XP002161278, ISSN: 0036-8075 *
WEBER GEORG F ET AL: "The immunology of Eta-1/Osteopontin.", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 7, no. 3, 1996, pages 241 - 248, XP000982501, ISSN: 1359-6101 *
YU X Q ET AL: "A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat.", PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, (1998 JAN-FEB) 110 (1) 50-64., XP000982503 *

Also Published As

Publication number Publication date
AU4357500A (en) 2000-11-02
JP2003517284A (en) 2003-05-27
WO2000063241A2 (en) 2000-10-26
EP1175223A2 (en) 2002-01-30
WO2000063241A9 (en) 2002-03-28
CA2370129A1 (en) 2000-10-26
BR0009791A (en) 2002-01-08
AU773350B2 (en) 2004-05-20
IL145891A0 (en) 2002-07-25
MXPA01010332A (en) 2002-09-18

Similar Documents

Publication Publication Date Title
WO2000063241A3 (en) Methods and compositions for modulating an immune response
MXPA02001911A (en) Human ctla 4 antibodies and their uses.
DK0484281T3 (en)
AU4612093A (en) Soluble ligands for CD40
NL1003813A1 (en) Device for the treatment of airway obstructions.
HK1125943A1 (en) Immunostimulatory sequence oligonucleotides and methods of using the same
CA2323929A1 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU5067100A (en) Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily
EP2289550A3 (en) Ultra high affinity neutralizing antibodies
EP0945135A3 (en) Treatment of alzheimer's disease and modulation of immune system with Delta5-Androstenes
WO2001035991A3 (en) Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
CA2109977A1 (en) Giardia vaccines
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
EP1385993B8 (en) Method of detecting and treating tuberous sclerosis complex associated disorders
AU2224197A (en) Drug trial assay system
IN170314B (en)
AUPN115095A0 (en) Analysis of and compositions and methods for the treatment of disease
AU5244998A (en) Morphogen-induced regeneration of sense perceptory tissues
Janssen Locus heterogeneity and the molecular basis of tuberous sclerosis
MX9802809A (en) Urease for the treatment of helicobacter pylori infections.
EP1001123A3 (en) Door or window hinge
WO2003097684A8 (en) Card-4 molecules and uses thereof
AU2002329036A1 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010332

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2370129

Country of ref document: CA

Ref country code: CA

Ref document number: 2370129

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 612329

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923454

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000923454

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/18-18/18; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000923454

Country of ref document: EP